-Amarin’s EPA medicine called Vascepa recently showed a 25% relative risk reduction in newly announced data from a CardioVascular Outcomes Trial.
-Today I breakdown the results and talk about how it compares to other CVOT data and whether Amarin is likely to rival companies with a LDL-c lowering drug pipelines.
Click to access AMRN%20Investor%20Deck%20Sept%20Post%20R-IT%20v3.pdf
*this is not investment/trading advice*
Follow me @matthewlepoire